POET Technologies (POET) is drawing fresh attention after reporting full year 2025 results, alongside an update on its shift toward high volume execution, backed by more than US$375 million in recently secured financing.

Despite the fresh funding and high volume ambitions, recent trading has been weak, with a 1 month share price return of an 18.96% decline and a year to date share price return of a 21.79% decline. The 1 year total shareholder return of 45.08% points to earlier momentum that has cooled in the short term as investors reassess execution risks around the scale up plan.

If this shift toward execution has you looking at other semiconductor names tied to AI infrastructure, it could be a good moment to scan 36 AI infrastructure stocks

With POET trading below analyst price targets after a weak short term run and still reporting modest revenue alongside a sizeable loss, the real question is whether you are seeing a mispriced growth story or a market that is already discounting what comes next.

Most Popular Narrative: 67.8% Undervalued

According to the most followed narrative, POET's fair value of $17.37 sits well above the last close at $5.60, framing a wide valuation gap that rests on an aggressive growth and profitability path for its Optical Interposer platform.

POET Technologies is not just a component manufacturer; it is the architect of the "optical nervous system" for the AI era. While the market focuses on GPUs (Nvidia), the critical bottleneck has shifted to data transfer speeds and energy efficiency. POET's "Optical Interposer" platform addresses both. With confirmed partnerships (Foxconn, Mitsubishi, Celestial AI) and a $250 million capital injection, the company has reduced its financial risk profile and is entering a hyper growth phase.

Want to see what kind of revenue ramp and margin profile could support that gap to fair value? The narrative leans heavily on rapid scale up, rising profitability, and a rich future earnings multiple tied to AI infrastructure demand, but the exact assumptions sit beneath the surface for those who read it in full.

Result: Fair Value of $17.37 (UNDERVALUED)

However, the thesis could be knocked off course if the currently modest US$0.76 million of revenue fails to scale, or if losses near US$50.6 million persist longer than expected.

Another View: A Richer Price Tag on Book Value

The user narrative focuses on growth and fair value at $17.37, but the market is sending a different signal when you look at P/B. POET trades at 12.9x book value, compared with 4.3x for the US Semiconductor industry and an average of negative 0.4x for direct peers, which makes the current price look demanding rather than cheap.

That kind of premium can signal confidence in future execution or simply raise the bar for what the business has to deliver next. The key question is whether you see that gap as valuation risk or a price worth paying for the growth story.

Next Steps

With sentiment clearly split between upside potential and valuation risk, it makes sense to move quickly and check the underlying data yourself so you are not relying on anyone else's conviction. A useful shortcut is to review the balance between the company's 1 key reward and 4 important warning signs in our 1 key reward and 4 important warning signs

Looking for more investment ideas?

If POET has sparked your interest, do not stop here. Broaden your watchlist with a few focused stock ideas that match different investing styles.

• Target potential mispricings by scanning 63 high quality undervalued stocks that currently pair quality fundamentals with attractive valuations.
• Strengthen the income side of your portfolio by checking out 12 dividend fortresses offering higher yields with an emphasis on resilience.
• Get ahead of the crowd by reviewing the screener containing 25 high quality undiscovered gems that combine solid financials with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.